Serveur d'exploration autour du libre accès en Belgique

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model

Identifieur interne : 000790 ( Main/Exploration ); précédent : 000789; suivant : 000791

Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model

Auteurs : Inge M C M. De Kok [Pays-Bas] ; Joost Van Rosmalen [Pays-Bas] ; Joakim Dillner [Suède] ; Marc Arbyn [Belgique] ; Peter Sasieni [Royaume-Uni] ; Thomas Iftner [Allemagne] ; Marjolein Van Ballegooijen [Pays-Bas]

Source :

RBID : ISTEX:43F90B8F18EF894CD7C5E5F2B4F131032C2FA249

Abstract

Objectives To investigate, using a Dutch model, whether and under what variables framed for other European countries screening for human papillomavirus (HPV) is preferred over cytology screening for cervical cancer, and to calculate the preferred number of examinations over a woman’s lifetime. Design Cost effectiveness analysis based on a Dutch simulation model. Base case analyses investigated the cost effectiveness of more than 1500 different screening policies using the microsimulation model. Subsequently, the policies were compared for five different scenarios that represent different possible scenarios (risk of cervical cancer, previous screening, quality associated test characteristics, costs of testing, and prevalence of HPV). Setting Various European countries. Population Unvaccinated women born between 1939 and 1992. Main outcome measures Optimal screening strategy in terms of incremental cost effectiveness ratios (costs per quality adjusted life years gained) compared with different cost effectiveness thresholds, for two levels of sensitivity and costs of the HPV test. Results Primary HPV screening was the preferred primary test over the age of 30 in many considered scenarios. Primary cytology screening was preferred only in scenarios with low costs of cytology and in scenarios with a high prevalence of HPV in combination with high costs of HPV testing. Conclusions Most European countries should consider switching from primary cytology to HPV screening for cervical cancer. HPV screening must, however, only be implemented in situations where screening is well controlled.

Url:
DOI: 10.1136/bmj.e670


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model</title>
<author>
<name sortKey="De Kok, Inge M C M" sort="De Kok, Inge M C M" uniqKey="De Kok I" first="Inge M C M" last="De Kok">Inge M C M. De Kok</name>
</author>
<author>
<name sortKey="Van Rosmalen, Joost" sort="Van Rosmalen, Joost" uniqKey="Van Rosmalen J" first="Joost" last="Van Rosmalen">Joost Van Rosmalen</name>
</author>
<author>
<name sortKey="Dillner, Joakim" sort="Dillner, Joakim" uniqKey="Dillner J" first="Joakim" last="Dillner">Joakim Dillner</name>
</author>
<author>
<name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name>
</author>
<author>
<name sortKey="Sasieni, Peter" sort="Sasieni, Peter" uniqKey="Sasieni P" first="Peter" last="Sasieni">Peter Sasieni</name>
</author>
<author>
<name sortKey="Iftner, Thomas" sort="Iftner, Thomas" uniqKey="Iftner T" first="Thomas" last="Iftner">Thomas Iftner</name>
</author>
<author>
<name sortKey="Van Ballegooijen, Marjolein" sort="Van Ballegooijen, Marjolein" uniqKey="Van Ballegooijen M" first="Marjolein" last="Van Ballegooijen">Marjolein Van Ballegooijen</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:43F90B8F18EF894CD7C5E5F2B4F131032C2FA249</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1136/bmj.e670</idno>
<idno type="url">https://api.istex.fr/document/43F90B8F18EF894CD7C5E5F2B4F131032C2FA249/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001157</idno>
<idno type="wicri:Area/Istex/Curation">001133</idno>
<idno type="wicri:Area/Istex/Checkpoint">000403</idno>
<idno type="wicri:doubleKey">0959-8138:2012:De Kok I:primary:screening:for</idno>
<idno type="wicri:Area/Main/Merge">000791</idno>
<idno type="wicri:Area/Main/Curation">000790</idno>
<idno type="wicri:Area/Main/Exploration">000790</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model</title>
<author>
<name sortKey="De Kok, Inge M C M" sort="De Kok, Inge M C M" uniqKey="De Kok I" first="Inge M C M" last="De Kok">Inge M C M. De Kok</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Erasmus MC, University Medical Center, Department of Public Health, PO Box 2040, 3000 CA Rotterdam</wicri:regionArea>
<wicri:noRegion>3000 CA Rotterdam</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Pays-Bas</country>
</affiliation>
</author>
<author>
<name sortKey="Van Rosmalen, Joost" sort="Van Rosmalen, Joost" uniqKey="Van Rosmalen J" first="Joost" last="Van Rosmalen">Joost Van Rosmalen</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Erasmus MC, University Medical Center, Department of Public Health, PO Box 2040, 3000 CA Rotterdam</wicri:regionArea>
<wicri:noRegion>3000 CA Rotterdam</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dillner, Joakim" sort="Dillner, Joakim" uniqKey="Dillner J" first="Joakim" last="Dillner">Joakim Dillner</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö</wicri:regionArea>
<wicri:noRegion>Malmö</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels</wicri:regionArea>
<placeName>
<settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sasieni, Peter" sort="Sasieni, Peter" uniqKey="Sasieni P" first="Peter" last="Sasieni">Peter Sasieni</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName type="university">Université de Londres</orgName>
</affiliation>
</author>
<author>
<name sortKey="Iftner, Thomas" sort="Iftner, Thomas" uniqKey="Iftner T" first="Thomas" last="Iftner">Thomas Iftner</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, University Hospital Tuebingen, Tuebingen</wicri:regionArea>
<placeName>
<region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Tübingen</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Van Ballegooijen, Marjolein" sort="Van Ballegooijen, Marjolein" uniqKey="Van Ballegooijen M" first="Marjolein" last="Van Ballegooijen">Marjolein Van Ballegooijen</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Erasmus MC, University Medical Center, Department of Public Health, PO Box 2040, 3000 CA Rotterdam</wicri:regionArea>
<wicri:noRegion>3000 CA Rotterdam</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">BMJ</title>
<title level="j" type="abbrev">BMJ</title>
<idno type="ISSN">0959-8138</idno>
<idno type="eISSN">1468-5833</idno>
<imprint>
<publisher>British Medical Journal Publishing Group</publisher>
<date type="published" when="2012">2012</date>
<biblScope unit="volume">344</biblScope>
</imprint>
<idno type="ISSN">0959-8138</idno>
</series>
<idno type="istex">43F90B8F18EF894CD7C5E5F2B4F131032C2FA249</idno>
<idno type="DOI">10.1136/bmj.e670</idno>
<idno type="href">bmj-344-bmj-e670.pdf</idno>
<idno type="ArticleID">deki874693</idno>
<idno type="local">bmj;344/mar05_1/e670</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0959-8138</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Objectives To investigate, using a Dutch model, whether and under what variables framed for other European countries screening for human papillomavirus (HPV) is preferred over cytology screening for cervical cancer, and to calculate the preferred number of examinations over a woman’s lifetime. Design Cost effectiveness analysis based on a Dutch simulation model. Base case analyses investigated the cost effectiveness of more than 1500 different screening policies using the microsimulation model. Subsequently, the policies were compared for five different scenarios that represent different possible scenarios (risk of cervical cancer, previous screening, quality associated test characteristics, costs of testing, and prevalence of HPV). Setting Various European countries. Population Unvaccinated women born between 1939 and 1992. Main outcome measures Optimal screening strategy in terms of incremental cost effectiveness ratios (costs per quality adjusted life years gained) compared with different cost effectiveness thresholds, for two levels of sensitivity and costs of the HPV test. Results Primary HPV screening was the preferred primary test over the age of 30 in many considered scenarios. Primary cytology screening was preferred only in scenarios with low costs of cytology and in scenarios with a high prevalence of HPV in combination with high costs of HPV testing. Conclusions Most European countries should consider switching from primary cytology to HPV screening for cervical cancer. HPV screening must, however, only be implemented in situations where screening is well controlled.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Allemagne</li>
<li>Belgique</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>Suède</li>
</country>
<region>
<li>Angleterre</li>
<li>Bade-Wurtemberg</li>
<li>District de Tübingen</li>
<li>Grand Londres</li>
<li>Région de Bruxelles-Capitale</li>
</region>
<settlement>
<li>Bruxelles</li>
<li>Londres</li>
<li>Tübingen</li>
</settlement>
<orgName>
<li>Université de Londres</li>
</orgName>
</list>
<tree>
<country name="Pays-Bas">
<noRegion>
<name sortKey="De Kok, Inge M C M" sort="De Kok, Inge M C M" uniqKey="De Kok I" first="Inge M C M" last="De Kok">Inge M C M. De Kok</name>
</noRegion>
<name sortKey="De Kok, Inge M C M" sort="De Kok, Inge M C M" uniqKey="De Kok I" first="Inge M C M" last="De Kok">Inge M C M. De Kok</name>
<name sortKey="Van Ballegooijen, Marjolein" sort="Van Ballegooijen, Marjolein" uniqKey="Van Ballegooijen M" first="Marjolein" last="Van Ballegooijen">Marjolein Van Ballegooijen</name>
<name sortKey="Van Rosmalen, Joost" sort="Van Rosmalen, Joost" uniqKey="Van Rosmalen J" first="Joost" last="Van Rosmalen">Joost Van Rosmalen</name>
</country>
<country name="Suède">
<noRegion>
<name sortKey="Dillner, Joakim" sort="Dillner, Joakim" uniqKey="Dillner J" first="Joakim" last="Dillner">Joakim Dillner</name>
</noRegion>
</country>
<country name="Belgique">
<region name="Région de Bruxelles-Capitale">
<name sortKey="Arbyn, Marc" sort="Arbyn, Marc" uniqKey="Arbyn M" first="Marc" last="Arbyn">Marc Arbyn</name>
</region>
</country>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Sasieni, Peter" sort="Sasieni, Peter" uniqKey="Sasieni P" first="Peter" last="Sasieni">Peter Sasieni</name>
</region>
</country>
<country name="Allemagne">
<region name="Bade-Wurtemberg">
<name sortKey="Iftner, Thomas" sort="Iftner, Thomas" uniqKey="Iftner T" first="Thomas" last="Iftner">Thomas Iftner</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000790 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000790 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Belgique
   |area=    OpenAccessBelV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:43F90B8F18EF894CD7C5E5F2B4F131032C2FA249
   |texte=   Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model
}}

Wicri

This area was generated with Dilib version V0.6.25.
Data generation: Thu Dec 1 00:43:49 2016. Site generation: Wed Mar 6 14:51:30 2024